Invasive Pulmonary Aspergillosis: History
View Latest Version
Please note this is an old version of this entry, which may differ significantly from the current revision.
Contributor:
Marie-Pierre Ledoux
,
Raoul Herbrecht

Invasive pulmonary aspergillosis is growing in incidence, as patients at risk are growing in diversity. Outside the classical context of neutropenia, new risk factors are emerging or newly identified, such as new anticancer drugs, viral pneumonias and hepatic dysfunctions. Clinical signs remain unspecific in these populations and the diagnostic work-up has considerably expanded. Computed tomography is key to assess the pulmonary lesions of aspergillosis, whose various features must be acknowledged. Positron-emission tomography can bring additional information for diagnosis and follow-up in specific cases. The mycological argument for diagnosis is rarely fully conclusive, as biopsy from a sterile site is challenging in most clinical contexts. In patients with a risk and suggestive radiological findings, probable invasive aspergillosis is diagnosed through blood and bronchoalveolar lavage fluid samples by detecting galactomannan or DNA, or by direct microscopy and culture for the latter. Diagnosis is considered as a possible invasive mold disease in lack of mycological criterion. 

  • leukemia
  • hematopoietic stem cell transplantation
  • solid organ transplantation
  • neutropenia
  • galactomannan

1. Clinical and Radiological Features

1.1. Clinical Features

Symptoms of invasive pulmonary aspergillosis (IA) are not specific and it is therefore recommended to adjust the clinician’s awareness according to the risk level of their patients in order to prescribe prompt and relevant further investigations. Fever refractory to, or recrudescent despite, antibiotics is often the first and sometimes the only symptom of IA. Although frequent, fever can be missed in some patients, for instance in those receiving corticosteroids. Cough, sputum production, hemoptysis, pleuritic chest pain or rub, dyspnea or bronchospasm are associated with pulmonary localization of IA.

1.2. Radiological Features

Chest radiograph is an obsolete procedure whenever chest computed tomographic (CT-scan) is available [1][2]. Contrast agents are usually not necessary for diagnosis but can be useful in assessing the risk of hemoptysis if a lesion is close to a large vessel. Depending on its mechanism of extension, IA can present with two different CT-scan patterns: angio-invasive pattern and airway-invasive pattern [3].
The angio-invasive pattern is the radiological translation of the penetration of hyphae through the vessels wall, leading to fungal thrombi causing necrosis and hematogenous dissemination. It has been classically associated with severe neutropenia and consists of nodules often surrounded by ground-glass opacity, translating perilesional hemorrhage and forming of the halo sign [4]. The halo sign is considered highly suggestive of neutropenia-related IA, but it is not specific and can be seen is various conditions such as other invasive mold diseases (IMD), bacterial infections, primary or metastatic cancers, granulomatous with polyangiitis, bronchiolitis obliterans with organizing pneumonia, or focal lung injury. It is also important to take into account the potential variations of this typical lesion through time: an early CT-scan might show micronodules, whereas a late CT-scan might miss the halo of ground-glass opacity, that classically disappears after 5 to 10 days [5]. In an even later setting, the recovery from neutropenia induces a necrotic retraction of this primary lesion and gives the aspect of an air crescent in a nodule. This air crescent can eventually widen into a cavity, first thick-walled and finally thin-walled.
The airway-invasive pattern is mostly seen in non-neutropenic patients [3][5]. Its CT-scan reflects the endobronchial dissemination of infection with thickened bronchial walls with multiple centrilobular nodules, resulting in the typical tree-in-bud pattern. This pattern is widely shared by other pulmonary infections, from mycobacteria to viruses and is therefore not a strong argument for IA if no other documentation is brought, all the more so as coinfections are frequent. This pattern is also associated with a worse functional course with mechanical ventilation requirement [6].
Both patterns can be intricated in the same patient, showing how complex the IA evolution can be [3]. Moreover, some patients present with only area of consolidation or ground glass opacities [7][8]. Therefore, whether the CT-scan shows a very specific or a non-specific aspect, further investigations must be performed in search for a mycological criterion for IA. CT-scan is also useful for treatment evaluation.

1.3. Bronchoscopic Features

Guided by CT-scan findings, a bronchoscopy must be performed whenever the patient is in adequate condition (i.e., without severe hypoxia or bleeding) to help better establish the diagnosis through a bronchoalveolar lavage (BAL) [1]. A higher yield has been obtained in allogeneic stem cell transplant (alloSCT) recipients with new pulmonary infiltrates when bronchoscopy was performed within the first 4 days of presentation [9]. Saline is usually used for lavage in the segmental or subsegmental bronchus of the most suggestive area identified on the CT-scan. BAL fluid (BALF) must be assessed by direct examination for cytology, Gram and fungal staining. Bacterial and fungal culture must be performed, as well as mycobacterial if relevant. Biomarkers and polymerase chain reaction (PCR) should be assessed as available and clinically relevant: Aspergillus galactomannan (GM), (1,3)-β-D-glucan (BDG), Aspergillus and Mucorales PCR, Pneumocystis jirovecii or Toxoplasma PCR, viral PCR. BAL has a pivotal role in detecting polymicrobial infections, the frequency of which can reach 20% in patients with hematological malignancies and should not be neglected [10][11].

2. Microbiological Findings

2.1. Samples

Respiratory samples are diverse and not equal in terms of sensitivity and specificity. While the gold-standard for the diagnosis of IA is bronchoalveolar lavage fluid (BALF), its availability relies on the patient’s fitness and willingness for a not innocuous procedure. Sputum is usually more easily available, but a good quality sample can require physiotherapist maneuvers for patients with a little-productive cough. In intubated patients, tracheal aspirates or brushes are an interesting intermediate sample. However, both sputum and tracheal aspirates may lead to a confusion between infection and colonization if not interpreted with caution.
Culture-positive blood-samples are exceptional, in spite of the angio-invasive capacity of Aspergillus species [12]. Nevertheless, blood samples are part of the diagnostic work-up of IA, in the search for biomarkers and fungal DNA. According to manufacturer specifications, tests can be performed on whole blood, on plasma or serum. Thresholds for positivity may vary depending on the nature of the sample.

2.2. Direct Microscopy

Microscopic examination should be performed on all the available respiratory samples (BALF, tracheal aspiration or sputum), in spite of its low yield. Performance can be enhanced by the use of calcofluor-white [13]. Aspergillus is identified as a septate hyphae with dichotomous acute angle branching.

2.3. Culture

Commonly used media for Aspergillus culture are Sabouraud-dextrose, brain-heart-infusion or potato-dextrose agar [13]. Chloramphenicol is used to avoid competition with bacteria, while cycloheximide can be used to reduce environmental fungal contamination but might reduce the yield. Additional specialized media can be used to select Aspergillus species. Culture should be incubated at 30 °C for 21 days in a humidified environment. Mass spectrometry identification (MALDI-TOF) or genomic sequencing can be used on positive culture if microscopy does not enable a species identification [14][15]. Even more importantly, a positive culture enables testing of the strain’s sensitivity to antifungals.

2.4. Antibody

As IA is associated with immunosuppression, the lack of detection of antibodies directed against Aspergillus cannot be used as a diagnostic argument, contrary to the setting of ABPA or CPA [16]. Some patients still present with a humoral response leading to the detection of such antibodies within a mean time of 10 days after the onset of IA. The presence of anti-Aspergillus antibodies may decrease the sensitivity of the galactomannan detection test [17].

2.5. Galactomannan

GM is a polysaccharide component of the fungal cell wall of Aspergillus. GM detection is validated in serum, BALF and cerebrospinal fluid, with a better sensitivity than culture, and feasible but not validated in sputum and tissue biopsies. The results are expressed as an index in comparison to a control. The cut-off for positivity in serum is still controversial: single value over 0.5 is recommended by the manufacturer, while experts suggest a cut-off over 0.7 for a single test or two consecutive tests > 0.5 [18]. In BALF too, there is no consensus between >0.5 and >1.0, although a recent meta-analysis including 19 articles concluded in favor of the >0.5 cut-off associated with a sensitivity of 89% and a specificity of 79% [19].
Its high sensitivity has made GM detection an important part of diagnostic work-up for suspected IA in neutropenic patients. It can reach 60 to 80% in hematology patients but is lower in non-neutropenic patients and poor in the setting of anti-mold prophylaxis [17][20][21]. GM can be considered as very specific, but some cross reactivity can occur with other molds or dimorphic fungi such as Fusarium sp., Alternaria sp., Acremonium sp., Penicillium sp., Paecylomyces sp., Wangiella dermatitidis, Histoplasma capsulatum or Blastomyces dermatitidis [21]. Use of beta-lactam antibiotics or severe mucosal lesions including graft versus host disease (GVHD) have led to false positive tests in serum, while some saline solutions used in BAL have led to false positive tests in BALF.
When positive, an early decrease of serum GM index has been associated with a higher favorable response rate [22].

2.6. (1,3)-β-D-Glucan

Detection of BDG in serum might add sensitivity to the diagnostic work-up [23][24]. However, as this glucan is a component of the cell wall of most fungi, including Aspergillus but also Candida and Pneumocystis, its usefulness is limited by a lack of specificity. As BDG is not produced by Mucorales and Cryptococcus, it can still be of help in differential diagnosis. BDG can be detected also in BALF, but its poor specificity once again limits its usefulness [25].

2.7. Polymerase Chain Reaction

Aspergillus PCR has long lacked availability and standardization and is therefore less developed than GM use. These obstacles have now been overcome and PCR is included in routine diagnostic work-up with commercial kits based on serum, plasma or BALF samples [26][27][28][29][30]. Other samples can be analyzed, such as fresh tissue or formalin fixed and paraffin wax embedded tissue [31].
PCR sensitivity is high and can reach >90% in routine blood samples [32]. Its combination with GM detection results in BALF has been suggested to reach 96% sensitivity [33]. PCR specificity is, as expected, very high, up to 100% in some studies [34]. Cross-reactivities have nevertheless been reported with other molds such as Penicillium spp., Fusarium spp. and Rhizopus oryzae [35].
An additional value of PCR is the possibility of using probes against resistance-associated mutations, for the detection of azole-resistance, for instance [36].

2.8. Point of Care Tests

Point of care tests, also known as “bedside testing,” are particularly useful for rapid start to relevant antifungal therapy. Two of them available and European conformity CE-marked: lateral flow device AspLFD (OLM Diagnostics, Newcastle-on-Tyne, UK) detecting an extracellular glycoprotein associated with Aspergillus growth, and lateral flow assay (IMMY, Norman, OK, USA) detecting GM [37][38]. Sensitivity and specificity are over 70% [39][40].

3. Diagnostic Criteria

3.1. EORTC-MSG Criteria

Confronted with the heterogeneity of features of IA reported in international literature, experts of the EORTC-MSG (European Organization for the Research and Treatment of cancer/Mycosis Study Group) issued as early as 2002 a system of criteria enabling determination of three levels of diagnostic certainty [41]. This system was not intended for clinical purpose and did not aim at refraining the start of a treatment due to lack of a criterion. The intent is harmonization of the clinical trials for a better understanding of their results. To account for improvements in diagnostic tools and growing variability of radiological findings associated with IA, updates have been issued in 2008 and 2020 [42][43].
An IA is considered to be proven in the case of a positive mycology or histopathology of a normaly sterile site obtained in a sterile manner. This is restricted to needle aspirations and biopsies as opposed to BAL fluid. Positive mycology can consist of a positive culture, a positive PCR or DNA sequencing. Positive histopathology consists of a sample in which hyphae are seen accompanied by evidence of tissue damage. If an identification of the mold is not performed, the diagnosis will be of IMD rather than IA.
Other levels of diagnostics levels of IA require a more thorough examination of the whole patient’s situation [43]. The host criterion relies on the presence of a known risk factor among the following: recent neutropenia (neutrophils < 0.500 G/L for more than 10 days), active hematological malignancy, alloSCT, solid organ transplantation, prolonged use of corticosteroids at a minimum dose of 0.3 mg/kg/d of prednisone or equivalent for more than 3 weeks, acute GvHD, T-cell suppressants, B-cell suppressants, inherited severe immunodeficiency. The clinical criterion for pulmonary aspergillosis is met in case of dense, well-circumscribed lesion with or without a halo sign, or an air crescent sign, or a cavity, or a wedge-shaped and segmental or lobar consolidation, whereas the clinical criterion for tracheobronchitis requires a tracheobronchial ulceration, nodule, pseudo-membrane, plaque or eschar seen on bronchoscopy. The mycological criterion is met in case of a positive direct microscopy or culture in sputum, BALF, bronchial brush or aspirate, or GM detected in blood ≥ 1.0, or in BALF ≥ 1.0 or both blood ≥ 0.7 and BALF ≥ 0.8, or a PCR positive in blood twice or in BALF twice (first analysis and duplicate) or once in both blood and BALF.
The diagnosis is probable IA if host criterion, clinical criterion and mycological criterion are all met. It is possible IMD if only host and clinical criterion are met.

3.2. AspICU

In spite of their focus-widening updates, the EORTC-MSG criteria remain restrictive with regard to a large category of patients susceptible to developing IA, particularly in critical care setting. Therefore, parallel diagnostic criteria were developed more adapted to critically ill patients, the Aspergillosis Intensive Care Unit algorithm, known as AspICU [44]. The proven IA category shares the definition of the EORTC-MSG proven IA. The IA is considered putative in cases in which four criteria are met: the entry criterion is Aspergillus-positive lower respiratory tract specimen culture; the clinical criterion comprises refractory or recrudescent fever despite antibiotics, pleuritic chest pain or rub, hemoptysis, dyspnea or respiratory insufficiency; the radiological criterion consists of an abnormal medical imaging by portable chest X-ray or CT scan of the lungs; the fourth criterion can be either a host risk factor (neutropenia, cytotoxic-treated hematological or oncological malignancy, glucocorticoid treatment or immunodeficiency) or a mycological finding: semiquantitative Aspergillus-positive culture of BALF without bacterial growth together with a positive cytological smear showing branching hyphae. If any of the four criteria is lacking, the case is considered a colonization.
To address the data provided by biomarkers, a new algorithm, BM-AspICU, was proposed [45]. The entry criterion is either positive Aspergillus in the lower respiratory tract, a radiological sign, or a clinical sign such as described in AspICU. If the patient has a “strong” host factor as defined by EORTC-MSG, a combination of an abnormal imaging and a mycological criterion are sufficient to diagnose a probable IA. If the patient only has a “weak” host factor as defined in AspICU, the combination of a clinical, a radiological and two mycological criteria are needed for the diagnosis of probable IA. Otherwise, the diagnosis is colonization.

3.3. Invasive Aspergillosis in Specific Conditions

More and more often described as a specific entity, influenza-associated pulmonary aspergillosis (IAPA) has its own consensual algorithm for diagnosis, associating pulmonary infiltrates in the setting of PCR-positive influenza with either tracheobronchitis, GM in serum or BALF, culture-positive BALF, or culture-positive sputum associated with an image of cavitation, to draw the diagnosis of probable IAPA [46].
With the high prevalence of Aspergillus-positive samples in COVID19-patients, a consensus for COVID19-associated invasive aspergillosis (CAPA) had to be found in the literature documenting the epidemy. A system of clinical, radiological and mycological criteria was proposed [47]. The clinical criteria are similar to that of AspICU: refractory fever, pain, pleuritic rub, dyspnea or hemoptysis. The radiological criterion consists of a pulmonary infiltrate or a cavity. The association of both with a strong mycological criterion (microscopy, culture, GM or PCR positive in BALF) leads to the diagnosis of probable CAPA. Their association with a weak mycological criterion (microscopy, culture, GM or PCR positive in bronchial aspiration) prompts the diagnosis of possible CAPA.

4. Treatment

4.1. Amphotericin B and Lipid Formulations

The first antifungal to show activity against Aspergillus was historically the polyene amphotericin B deoxycholate, whose poor safety profile has now led to recommendation against its use [48][49]. It is nevertheless still useful in low-resource settings [50].
An important improvement came from lipid formulations of amphotericin B, i.e., liposomal amphotericin B (L-amB), amphotericin B lipid complex (ABLC) and colloidal dispersion (ABCD). All were associated with less nephrotoxicity, and none with lower efficacy than amphotericin B  deoxycholate [51][52]. Exhibiting the best safety-profile, L-amB has eventually become the most widely available and used among the lipid formulations of amphotericin B, with a documented efficacy against IA [53]. The usual dosage against Aspergillus is 3 mg/kg/day and attempts to enhance antifungal activity with higher dosage in highly immunocompromised patients have proven disappointing. L-amB is particularly useful in the setting of a breakthrough infection under azole prophylaxis or in salvage therapy [38]. Aerosolization of amphotericin B and L-amB can also be used as a prophylaxis for IA, the latter showing a better tolerance [54][55][56].

4.2. Azoles

Inhibiting the synthesis of membrane component ergosterol, azoles play a key role in the management of many fungal infections [57]. Fluconazole lacking any efficacy on Aspergillus, the first azole used in the treatment of IA was itraconazole, with 39% patients having a complete or partial response at the end of treatment but a limiting toxicity and concerns about bioavailability [58].
A major step in IA treatment was made with the development of voriconazole. In the pivotal randomized trial comparing voriconazole to amphotericin B deoxycholate in IA treatment, successful outcomes reached 52.8% vs. 31.6% [48][59]. Tolerability of voriconazole is generally good, with a restriction due to frequent liver toxicity, visual and neurological side-effects and an interaction profile that may lead to difficulties in managing co-administration with hematological drugs such as cyclosporine, midostaurine or venetoclax. Rarely, prolonged use can lead to phototoxicity, skin carcinomas, peripheral neuropathy and periostitis [60]. Therapeutic-drug monitoring is available and should be used. The advised dosage is 6 mg/kg bid for a charging period of 24 h followed by 4 mg/kg bid. Voriconazole is recommended as a first-line treatment by IDSA, ECIL and ESCMID [1][2][49].
Posaconazole was first used in second line treatment for patients refractory to or intolerant of conventional antifungal therapy, with a satisfactory success rate of 42% [61]. In terms of tolerance, posaconazole exhibits a better safety profile than voriconazole [62]. This tolerability has allowed usage as a prophylaxis, all the more so since delayed-release tablets have enhanced bioavailability that used to be a concern [63]. Another interesting advantage of posaconazole upon voriconazole is its activity against Mucorales [64][65], for which differential diagnosis with IA can be challenging. Direct comparison between voriconazole and posaconazole in the treatment of IA has recently been achieved and shows the absence of inferiority of the latter, with a better safety-profile [62]. Recommended dosage is 300 mg bid for 1 day, followed by 300 mg qod and therapeutic drug monitoring with a target trough of 0.7 mg/L for prophylaxis or 1.0 mg/L for treatment.
Isavuconazole is the latest approved azole and shows satisfactory activity against Aspergillus, combined with an excellent safety profile. It has been compared with voriconazole in a randomized double-blind study [66], that demonstrated non-inferiority in terms of efficacy with a similar survival at week 6 and week 12. It was better tolerated with less hepatic, visual and cutaneous adverse events, and can therefore be of particular interest in the treatment of patients at risk of hepatic impairment. Moreover, its interaction profile with various drugs is more easily managed and leads to less dosage adaptations of concomitant therapies. A meta-analysis of isavuconazole trials concluded that its efficacy is comparable to both voriconazole and L-amB [67]. Besides, isavuconazole shows an interesting activity against Mucorales [68].

4.3. Echinocandins

Echinocandins are BDG-synthesis inhibitors that show mitigated activity against IA [69]. Caspofungin was first used as a second line therapy for IA patients with intolerance or failure of previous therapy and led to an encouraging 45% of favorable responses [70]. In first line therapy, it has been tried in neutropenic patients and alloSCT patients with results below expectations (53% and 50% survival at week 12, respectively), and is therefore not recommended by guidelines [71][72]. Micafungin and anidulafungin have insufficient activity against Aspergillus to be used as treatment in IA. On the other hand, the upcoming rezafungin shows promising activity against Aspergillus in vitro and mouse models [73].

4.4. Perspectives

Other new antifungals are awaited [74]. Ibrexafungerp, a BDG-synthesis inhibitor, is currently being tried in combination with voriconazole against voriconazole monotherapy in the setting of IA (NCT03672292; https://clinicaltrials.gov/, accessed on 22 January 2022) after promising results in vitro and mouse models in combination with isavuconazole [75][76].
Olorofim, an inhibitor of dihydro-oroate dehydrogenase, is currently being tried against L-amB in the setting of IA after promising results in vitro and in mouse models of neutropenia [77][78].
Fosmanogepix (APX001), an inhibitor of the fungal enzyme Gwt1, is currently in phase 2 trial after promising preclinical results [79].
Opelconazole is a new triazole designed for inhalation with a sustained lung residency which might be of use for prophylaxis or treatment of IA [74].

4.5. Combination Therapies

Several publications have explored the efficacy of combination therapy: L-amB and caspofungin, voriconazole and caspofungin or voriconazole and anidulafungin [80][81][82][83][84]. Only the latter was a prospective randomized large-scale study and no superiority of the combination therapy arm was demonstrated. Therefore, guidelines do not recommend the use of two antifungals for treating IA [1][2][49]. However, combination can be argued for in the context of high azole-resistance prevalence and might be of use in salvage therapy.

4.6. Antifungal Strategies

The availability of many different antifungals with various efficacy and safety profiles prompts the establishment of management strategies [85]. The relevance of anti-mold prophylaxis for patients at risk after AML-remission induction therapy or during alloSCT procedure must be discussed on the basis of the local epidemiology [86]. Other situations that can also be an indication for prophylaxis are not as consensual as yet.
Empirical therapy, taking place at the start of antifungal agents in any antibacterial-resistant fever for at-risk neutropenic patients, was proposed four decades ago and decreased morbidity and mortality. However, following studies had conflicting results [87][88]. Concerns are raised about exposing patients to useless toxicities, promoting resistance, and about overall costs.
Preemptive therapy, based on a diagnostic-driven start of antifungals, was made possible through the improvement of efficiency and availability of biomarkers and CT-scan. It has been shown to lessen the consumption of antifungals without impairing patients’ outcome [89][90].
Whichever way the start of treatment is decided, every clinician is faced with the decision regarding the discontinuation of antifungal therapy. Standard recommendations point towards 6 to 12 weeks, but the treatment duration should be tailored to the patient’s situation [27]. Response assessment with CT-scan, or perhaps PET-CT, can help in the decision-making. If the patient remains at-risk, treatment is often switched into secondary prophylaxis, sometimes with the same antifungal.
An algorithm has been suggested to decide when to stop antifungal treatment in patients with hematological malignancies and IA. It integrates status of the hematological malignancy, recovery from neutropenia, negative mycology, clinical and imaging response to antifungal therapy and planned further chemotherapy and immunosuppression [91].

This entry is adapted from the peer-reviewed paper 10.3390/jof9020131

References

  1. Patterson, T.F.; Thompson, G.R., III.; Denning, D.W.; Fishman, J.A.; Hadley, S.; Herbrecht, R.; Kontoyiannis, D.P.; Marr, K.A.; Morrison, V.A.; Nguyen, M.H.; et al. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 2016, 63, e1–e60.
  2. Ullmann, A.J.; Aguado, J.M.; Arikan-Akdagli, S.; Denning, D.W.; Groll, A.H.; Lagrou, K.; Lass-Flörl, C.; Lewis, R.E.; Munoz, P.; Verweij, P.E.; et al. Diagnosis and management of Aspergillus diseases: Executive summary of the 2017 ESCMID-ECMM-ERS guideline. Clin. Microbiol. Infect. 2018, 24, e1–e38.
  3. Bergeron, A.; Porcher, R.; Sulahian, A.; De Bazelaire, C.; Chagnon, K.; Raffoux, E.; Vekhoff, A.; Cornet, M.; Isnard, F.; Brethon, B.; et al. The strategy for the diagnosis of invasive pulmonary aspergillosis should depend on both the underlying condition and the leukocyte count of patients with hematologic malignancies. Blood 2012, 119, 1831–1837.
  4. Greene, R.E.; Schlamm, H.T.; Oestmann, J.-W.; Stark, P.; Durand, C.; Lortholary, O.; Wingard, J.R.; Herbrecht, R.; Ribaud, P.; Patterson, T.F.; et al. Imaging findings in acute invasive pulmonary aspergillosis: Clinical significance of the halo sign. Clin. Infect. Dis. 2007, 44, 373–379.
  5. Prasad, A.; Agarwal, K.; Deepak, D.; Atwal, S.S. Pulmonary aspergillosis: What CT can offer before it is too late! J. Clin. Diagn. Res. 2016, 10, TE01–TE05.
  6. Munoz, P.; Vena, A.; Cerón, I.; Valerio, M.; Palomo, J.; Guinea, J.; Escribano, P.; Martínez-Sellés, M.; Bouza, E.; Promulga Project Group. Invasive pulmonary aspergillosis in heart transplant recipients: Two radiologic patterns with a different prognosis. J. Heart Lung Transplant. 2014, 33, 1034–1040.
  7. Herbrecht, R.; Guffroy, B.; Danion, F.; Venkatasamy, A.; Simand, C.; LeDoux, M.-P. Validation by real-life data of the new radiological criteria of the revised and updated consensus definition for invasive fungal diseases. Clin. Infect. Dis. 2020, 71, 2773–2774.
  8. Jin, J.; Wu, D.; Liu, Y.; Pan, S.; Yan, J.L.; Aram, J.A.; Lou, Y.-J.; Meng, H.; Chen, X.; Zhang, X.; et al. Utility of CT assessment in hematology patients with invasive aspergillosis: A post-hoc analysis of phase 3 data. BMC Infect. Dis. 2019, 19, 471.
  9. Shannon, V.R.; Andersson, B.S.; Lei, X.; Champlin, E.R.; Kontoyiannis, D.P. Utility of early versus late fiberoptic bronchoscopy in the evaluation of new pulmonary infiltrates following hematopoietic stem cell transplantation. Bone Marrow. Transplant. 2010, 45, 647–655.
  10. Danion, F.; Duval, C.; Séverac, F.; Bachellier, P.; Candolfi, E.; Castelain, V.; Clere-Jehl, R.; Denis, J.; Dillenseger, L.; Epailly, E.; et al. Factors associated with coinfections in invasive aspergillosis: A retrospective cohort study. Clin. Microbiol. Infect. 2021, 27, 1644–1651.
  11. Hardak, E.; Avivi, I.; Berkun, L.; Raz-Pasteur, A.; Lavi, N.; Geffen, Y.; Yigla, M.; Oren, I. Polymicrobial pulmonary infection in patients with hematological malignancies: Prevalence, co-pathogens, course and outcome. Infection 2016, 44, 491–497.
  12. Kontoyiannis, D.P.; Sumoza, D.; Tarrand, J.; Bodey, G.P.; Storey, R.; Raad, I.I. Significance of aspergillemia in patients with cancer: A 10-year study. Clin. Infect. Dis. 2000, 31, 188–189.
  13. Lass-Florl, C. How to make a fast diagnosis in invasive aspergillosis. Med. Mycol. 2019, 57, S155–S160.
  14. Walsh, T.J.; Wissel, M.C.; Grantham, K.J.; Petraitiene, R.; Petraitis, V.; Kasai, M.; Francesconi, A.; Cotton, M.P.; Hughes, J.E.; Greene, L.; et al. Molecular detection and species-specific identification of medically important Aspergillus species by real-time PCR in experimental invasive pulmonary aspergillosis. J. Clin. Microbiol. 2011, 49, 4150–4157.
  15. Chalupova, J.; Raus, M.; Sedlářová, M.; Šebela, M. Identification of fungal microorganisms by MALDI-TOF mass spectrometry. Biotechnol. Adv. 2014, 32, 230–241.
  16. Richardson, M.D.; Page, I.D. Aspergillus serology: Have we arrived yet? Med. Mycol. 2017, 55, 48–55.
  17. Herbrecht, R.; Letscher-Bru, V.; Oprea, C.; Lioure, B.; Waller, J.; Campos, F.; Villard, O.; Liu, K.-L.; Natarajan-Amé, S.; Lutz, P.; et al. Aspergillus galactomannan detection in the diagnosis of invasive aspergillosis in cancer patients. J. Clin. Oncol. 2002, 20, 1898–1906.
  18. Marchetti, O.; Lamoth, F.; Mikulska, M.; Viscoli, C.; Verweij, P.; Bretagne, S. ECIL recommendations for the use of biological markers for the diagnosis of invasive fungal diseases in leukemic patients and hematopoietic SCT recipients. Bone Marrow. Transplant. 2012, 47, 846–854.
  19. Li, C.; Sun, L.; Liu, Y.; Zhou, H.; Chen, J.; She, M.; Wang, Y. Diagnostic value of bronchoalveolar lavage fluid galactomannan assay for invasive pulmonary aspergillosis in adults: A meta-analysis. J. Clin. Pharm. Ther. 2022, 47, 1913–1922.
  20. Pfeiffer, C.D.; Fine, J.P.; Safdar, N. Diagnosis of invasive aspergillosis using a galactomannan assay: A meta-analysis. Clin. Infect. Dis. 2006, 42, 1417–1427.
  21. Miceli, M.H.; Maertens, J. Role of non-culture-based tests, with an emphasis on galactomannan testing for the diagnosis of invasive aspergillosis. Semin. Respir. Crit. Care Med. 2015, 36, 650–661.
  22. Chai, L.Y.; Kullberg, B.-J.; Johnson, E.M.; Teerenstra, S.; Khin, L.W.; Vonk, A.G.; Maertens, J.; Lortholary, O.; Donnelly, P.J.; Schlamm, H.T.; et al. Early serum galactomannan trend as a predictor of outcome of invasive aspergillosis. J. Clin. Microbiol. 2012, 50, 2330–2336.
  23. Lamoth, F. Galactomannan and 1,3-beta-d-glucan testing for the diagnosis of invasive aspergillosis. J. Fungi. Basel 2016, 2, 22.
  24. Dichtl, K.; Forster, J.; Ormanns, S.; Horns, H.; Suerbaum, S.; Seybold, U.; Wagener, J. Comparison of beta-D-glucan and galactomannan in serum for detection of invasive aspergillosis: Retrospective analysis with focus on early diagnosis. J. Fungi. Basel 2020, 6, 253.
  25. Rose, S.R.; Vallabhajosyula, S.; Velez, M.G.; Fedorko, D.P.; VanRaden, M.J.; Gea-Banacloche, J.C.; Lionakis, M.S. The utility of bronchoalveolar lavage beta-D-glucan testing for the diagnosis of invasive fungal infections. J. Infect. 2014, 69, 278–283.
  26. Barnes, R.A.; White, P.L.; Morton, C.O.; Rogers, T.R.; Cruciani, M.; Loeffler, J.; Donnelly, J.P. Diagnosis of aspergillosis by PCR: Clinical considerations and technical tips. Med. Mycol. 2018, 56, 60–72.
  27. Patterson, T.F.; Donnelly, J.P. New concepts in diagnostics for invasive mycoses: Non-culture-based methodologies. J. Fungi. Basel 2019, 5, 9.
  28. White, P.L.; Barnes, R.A.; Springer, J.; Klingspor, L.; Cuenca-Estrella, M.; Morton, C.O.; Lagrou, K.; Bretagne, S.; Melchers, W.J.G.; Mengoli, C.; et al. Clinical performance of Aspergillus PCR for testing serum and plasma: A study by the European Aspergillus PCR Initiative. J. Clin. Microbiol. 2015, 53, 2832–2837.
  29. Chong, G.L.; Van De Sande, W.W.J.; Dingemans, G.J.H.; Gaajetaan, G.R.; Vonk, A.G.; Hayette, M.-P.; Van Tegelen, D.W.E.; Simons, G.F.M.; Rijnders, B.J.A. Validation of a new Aspergillus real-time PCR assay for direct detection of Aspergillus and azole resistance of Aspergillus fumigatus on bronchoalveolar lavage fluid. J. Clin. Microbiol. 2015, 53, 868–874.
  30. Denis, J.; Forouzanfar, F.; Herbrecht, R.; Toussaint, E.; Kessler, R.; Sabou, M.; Candolfi, E.; Letsher-Bru, V. Evaluation of two commercial real-time PCR kits for Aspergillus DNA detection in bronchoalveolar lavage fluid in patients with invasive pulmonary aspergillosis. J. Mol. Diagn. 2018, 20, 298–306.
  31. Paterson, P.J.; Seaton, S.; McLaughlin, J.; Kibbler, C.C. Development of molecular methods for the identification of Aspergillus and emerging moulds in paraffin wax embedded tissue sections. Mol. Pathol. MP 2003, 56, 368–370.
  32. Rath, P.M.; Steinmann, J. Overview of commercially available PCR assays for the detection of Aspergillus spp. DNA in patient samples. Front. Microbiol. 2018, 9, 740.
  33. Pelzer, B.W.; Seufert, R.; Koldehoff, M.; Liebregts, T.; Schmidt, D.; Buer, J.; Rath, P.-M.; Steinmann, J. Performance of the AsperGenius(R) PCR assay for detecting azole resistant Aspergillus fumigatus in BAL fluids from allogeneic HSCT recipients: A prospective cohort study from Essen, West Germany. Med. Mycol. 2020, 58, 268–271.
  34. Cruciani, M.; Mengoli, C.; Barnes, R.; Donnelly, J.P.; Loeffler, J.; Jones, B.L.; Klingspor, L.; Maertens, J.; Morton, O.C.; White, L.P. Polymerase chain reaction blood tests for the diagnosis of invasive aspergillosis in immunocompromised people. Cochrane Database Syst. Rev. 2019, 9, CD009551.
  35. Moura, S.; Cerqueira, L.; Almeida, A. Invasive pulmonary aspergillosis: Current diagnostic methodologies and a new molecular approach. Eur. J. Clin. Microbiol. Infect. Dis. 2018, 37, 1393–1403.
  36. Resendiz-Sharpe, A.; Van Holm, W.; Merckx, R.; Pauwels, M.; Teughels, W.; Lagrou, K.; Velde, G.V. Quantitative PCR effectively quantifies triazole-susceptible and triazole-resistant Aspergillus fumigatus in mixed infections. J. Fungi. Basel 2022, 8, 1120.
  37. Thornton, C.R. Development of an immunochromatographic lateral-flow device for rapid serodiagnosis of invasive aspergillosis. Clin. Vaccine Immunol. 2008, 15, 1095–1105.
  38. Jenks, J.D.; Mehta, S.R.; Taplitz, R.; Aslam, S.; Reed, S.L.; Hoenigl, M. Point-of-care diagnosis of invasive aspergillosis in non-neutropenic patients: Aspergillus Galactomannan Lateral Flow Assay versus Aspergillus-specific Lateral Flow Device test in bronchoalveolar lavage. Mycoses 2019, 62, 230–236.
  39. Mercier, T.; Schauwvlieghe, A.; de Kort, E.; Dunbar, A.; Reynders, M.; Guldentops, E.; Rijnders, B.; Verweij, P.; Lagrou, K.; Maertens, J. Diagnosing invasive pulmonary aspergillosis in hematology patients: A retrospective multicenter evaluation of a novel lateral flow device. J. Clin. Microbiol. 2019, 57, e01913–e1918.
  40. Hoenigl, M.; Eigl, S.; Heldt, S.; Duettmann, W.; Thornton, C.; Prattes, J. Clinical evaluation of the newly formatted lateral-flow device for invasive pulmonary aspergillosis. Mycoses 2018, 61, 40–43.
  41. Ascioglu, S.; Rex, J.H.; De Pauw, B.; Bennett, J.E.; Bille, J.; Crokaert, F.; Denning, D.W.; Donnelly, J.P.; Edwards, J.E.; Erjavec, Z.; et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: An international consensus. Clin. Infect. Dis. 2002, 34, 7–14.
  42. De Pauw, B.; Walsh, T.J.; Donnelly, J.P.; Stevens, D.A.; Edwards, J.E.; Calandra, T.; Pappas, P.G.; Maertens, J.; Lortholary, O.; Kauffman, C.A.; et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin. Infect. Dis. 2008, 46, 1813–1821.
  43. Donnelly, J.P.; Chen, S.C.; Kauffman, C.A.; Steinbach, W.J.; Baddley, J.W.; Verweij, P.E.; Clancy, C.J.; Wingard, J.R.; Lockhart, S.R.; Groll, A.H.; et al. Revision and update of the consensus definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. Clin. Infect. Dis. 2020, 71, 1367–1376.
  44. Blot, S.I.; Taccone, F.S.; Van den Abeele, A.-M.; Bulpa, P.; Meersseman, W.; Brusselaers, N.; Dimopoulos, G.; Paiva, J.A.; Misset, B.; Rello, J.; et al. A clinical algorithm to diagnose invasive pulmonary aspergillosis in critically ill patients. Am. J. Respir. Crit. Care Med. 2012, 186, 56–64.
  45. Hamam, J.; Navellou, J.C.; Bellanger, A.P.; Bretagne, S.; Winiszewski, H.; Scherer, E.; Piton, G.; Millon, L.; Ressif group Collaborative. New clinical algorithm including fungal biomarkers to better diagnose probable invasive pulmonary aspergillosis in ICU. Ann. Intensive. Care 2021, 11, 41.
  46. Verweij, P.E.; Rijnders, B.J.A.; Brüggemann, R.J.M.; Azoulay, E.; Bassetti, M.; Blot, S.; Calandra, T.; Clancy, C.J.; Cornely, O.A.; Chiller, T.; et al. Review of influenza-associated pulmonary aspergillosis in ICU patients and proposal for a case definition: An expert opinion. Intensive. Care Med. 2020, 46, 1524–1535.
  47. Koehler, P.; Bassetti, M.; Chakrabarti, A.; Chen, S.C.A.; Colombo, A.L.; Hoenigl, M.; Klimko, N.; Lass-Flörl, C.; Oladele, R.O.; Vinh, D.C.; et al. Defining and managing COVID-19-associated pulmonary aspergillosis: The 2020 ECMM/ISHAM consensus criteria for research and clinical guidance. Lancet Infect. Dis. 2021, 21, e149–e162.
  48. Herbrecht, R.; Denning, D.W.; Patterson, T.F.; Bennett, J.E.; Greene, R.E.; Oestmann, J.-W.; Kern, W.V.; Marr, K.A.; Ribaud, P.; Lortholary, O.; et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N. Engl. J. Med. 2002, 347, 408–415.
  49. Tissot, F.; Agrawal, S.; Pagano, L.; Petrikkos, G.; Groll, A.H.; Skiada, A.; Lass-Flörl, C.; Calandra, T.; Viscoli, C.; Herbrecht, R. ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients. Haematologica 2017, 102, 433–444.
  50. Driemeyer, C.; Falci, D.R.; Oladele, O.R.; Bongomin, F.; Ocansey, B.K.; Govender, N.P.; Hoenigl, M.; Gangneux, J.P.; Lass-Flörl, C.; Cornely, A.O.; et al. The current state of clinical mycology in Africa: A European Confederation of Medical Mycology and International Society for Human and Animal Mycology survey. Lancet Microbe. 2022, 3, e464–e470.
  51. Tiphine, M.; Letscher-Bru, V.; Herbrecht, R. Amphotericin B and its new formulations: Pharmacologic characteristics, clinical efficacy, and tolerability. Transpl. Infect Dis. 1999, 1, 273–283.
  52. Herbrecht, R.; Natarajan-Amé, S.; Nivoix, Y.; Letscher-Bru, V. The lipid formulations of amphotericin B. Expert Opin. Pharmacother. 2003, 4, 1277–1287.
  53. Cornely, O.A.; Maertens, J.; Bresnik, M.; Ebrahimi, R.; Ullmann, A.J.; Bouza, E.; Heussel, C.P.; Lortholary, O.; Rieger, C.; Boehme, A.; et al. Liposomal amphotericin B as initial therapy for invasive mold infection: A randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin. Infect. Dis. 2007, 44, 1289–1297.
  54. Schwartz, S.; Behre, G.; Heinemann, V.; Wandt, H.; Schilling, E.; Arning, M.; Trittin, A.; Kern, W.V.; Boenisch, O.; Bosse, D.; et al. Aerosolized amphotericin B inhalations as prophylaxis of invasive Aspergillus infections during prolonged neutropenia: Results of a prospective randomized multicenter trial. Blood 1999, 93, 3654–3661.
  55. Rijnders, B.J.; Cornelissen, J.J.; Slobbe, L.; Becker, M.J.; Doorduijn, J.K.; Hop, W.C.; Ruijgrok, E.J.; Lowenberg, B.; Vulto, A.; Lugtenburg, P.J.; et al. Aerosolized liposomal amphotericin B for the prevention of invasive pulmonary aspergillosis during prolonged neutropenia: A randomized, placebo-controlled trial. Clin. Infect Dis. 2008, 46, 1401–1408.
  56. Xia, D.; Sun, W.-K.; Tan, M.-M.; Zhang, M.; Ding, Y.; Liu, Z.-C.; Su, X.; Shi, Y. Aerosolized amphotericin B as prophylaxis for invasive pulmonary aspergillosis: A meta-analysis. Int. J. Infect Dis. 2015, 30, 78–84.
  57. Ramos, E.R.; Jiang, Y.; Hachem, R.; Kassis, C.; Kontoyiannis, D.P.; Raad, I. Outcome analysis of invasive aspergillosis in hematologic malignancy and hematopoietic stem cell transplant patients: The role of novel antimold azoles. Oncologist 2011, 16, 1049–1060.
  58. Denning, D.W.; Lee, J.Y.; Hostetler, J.S.; Pappas, P.; Kauffman, C.A.; Dewsnup, D.H.; Galgiani, J.N.; Graybill, J.R.; Sugar, A.M.; Catanzaro, A. NIAID Mycoses Study Group multicenter trial of oral itraconazole therapy for invasive aspergillosis. Am. J. Med. 1994, 97, 135–144.
  59. Herbrecht, R.; Patterson, T.F.; Slavin, M.A.; Marchetti, O.; Maertens, J.; Johnson, E.M.; Schlamm, H.T.; Donnelly, J.P.; Pappas, P.G. Application of the 2008 definitions for invasive fungal diseases to the trial comparing voriconazole versus amphotericin B for therapy of invasive aspergillosis: A collaborative study of the Mycoses Study Group (MSG 05) and the European Organization for Research and Treatment of Cancer Infectious Diseases Group. Clin. Infect Dis. 2015, 60, 713–720.
  60. Benitez, L.L.; Carver, P.L. Adverse effects associated with long-term administration of azole antifungal agents. Drugs 2019, 79, 833–853.
  61. Walsh, T.J.; Raad, I.; Patterson, T.F.; Chandrasekar, P.; Donowitz, G.R.; Graybill, R.; Greene, R.E.; Hachem, R.; Hadley, S.; Herbrecht, R.; et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: An externally controlled trial. Clin. Infect Dis. 2007, 44, 2–12.
  62. Maertens, J.A.; Rahav, G.; Lee, D.-G.; Ponce-De-León, A.; Sánchez, I.C.R.; Klimko, N.; Sonet, A.; Haider, S.; Vélez, J.D.; Raad, I.; et al. Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: A phase 3, randomised, controlled, non-inferiority trial. Lancet 2021, 397, 499–509.
  63. Leclerc, E.; Combarel, D.; Uzunov, M.; Leblond, V.; Funck-Brentano, C.; Zahr, N. Prevention of invasive Aspergillus fungal infections with the suspension and delayed-release tablet formulations of posaconazole in patients with haematologic malignancies. Sci. Rep. 2018, 8, 1681.
  64. Greenberg, R.N.; Mullane, K.; van Burik, J.-A.H.; Raad, I.; Abzug, M.J.; Anstead, G.; Herbrecht, R.; Langston, A.; Marr, K.A.; Schiller, G.; et al. Posaconazole as salvage therapy for zygomycosis. Antimicrob. Agents Chemother. 2006, 50, 126–133.
  65. van Burik, J.A.; Hare, R.S.; Solomon, H.F.; Corrado, M.L.; Kontoyiannis, D.P. Posaconazole is effective as salvage therapy in zygomycosis: A retrospective summary of 91 cases. Clin. Infect Dis. 2006, 42, e61–e65.
  66. Maertens, J.A.; Raad, I.I.; Marr, A.K.; Patterson, T.F.; Kontoyiannis, D.P.; Cornely, A.O.; Bow, E.J.; Rahav, G.; Neofytos, D.; Aoun, M.; et al. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): A phase 3, randomised-controlled, non-inferiority trial. Lancet 2016, 387, 760–769.
  67. Herbrecht, R.; Kuessner, D.; Pooley, N.; Posthumus, J.; Escrig, C. Systematic review and network meta-analysis of clinical outcomes associated with isavuconazole versus relevant comparators for patients with invasive aspergillosis. Curr. Med. Res. Opin. 2018, 34, 2187–2195.
  68. Marty, F.M.; Ostrosky-Zeichner, L.; Cornely, O.A.; Mullane, K.M.; Perfect, J.R.; Thompson, G.R.; Alangaden, G.J.; Brown, J.M.; Fredricks, D.N.; Heinz, W.J.; et al. Isavuconazole treatment for mucormycosis: A single-arm open-label trial and case-control analysis. Lancet Infect. Dis. 2016, 16, 828–837.
  69. Aruanno, M.; Glampedakis, E.; Lamoth, F. Echinocandins for the treatment of invasive aspergillosis: From laboratory to bedside. Antimicrob. Agents Chemother. 2019, 63, e00399-19.
  70. Maertens, J.; Raad, I.; Petrikkos, G.; Boogaerts, M.; Selleslag, D.; Petersen, F.B.; Sable, C.A.; Kartsonis, N.A.; Ngai, A.; Taylor, A.; et al. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin. Infect. Dis. 2004, 39, 1563–1571.
  71. Viscoli, C.; Herbrecht, R.; Akan, H.; Baila, L.; Sonet, A.; Gallamini, A.; Giagounidis, A.; Marchetti, O.; Martino, R.; Meert, L.; et al. An EORTC Phase II study of caspofungin as first-line therapy of invasive aspergillosis in haematological patients. J. Antimicrob. Chemother. 2009, 64, 1274–1281.
  72. Herbrecht, R.; Maertens, J.; Baila, L.; Aoun, M.; Heinz, W.; Martino, R.; Schwartz, S.; Ullmann, A.J.; Meert, L.; Paesmans, M.; et al. Caspofungin first-line therapy for invasive aspergillosis in allogeneic hematopoietic stem cell transplant patients: An European Organisation for Research and Treatment of Cancer study. Bone Marrow. Transplant. 2010, 45, 1227–1233.
  73. Wiederhold, N.P.; Najvar, L.K.; Jaramillo, R.; Olivo, M.; Wickes, B.; Catano, G.; Patterson, T.F. Extended-interval dosing of rezafungin against azole-resistant Aspergillus fumigatus. Antimicrob. Agents Chemother. 2019, 63, e01165-19.
  74. Hoenigl, M.; Sprute, R.; Egger, M.; Arastehfar, A.; Cornely, O.A.; Krause, R.; Lass-Flörl, C.; Prattes, J.; Spec, A.; Thompson, G.R., 3rd; et al. The antifungal pipeline: Fosmanogepix, ibrexafungerp, olorofim, opelconazole, and rezafungin. Drugs 2021, 81, 1703–1729.
  75. Angulo, D.A.; Alexander, B.; Rautemaa-Richardson, R.; Alastruey-Izquierdo, A.; Hoenigl, M.; Ibrahim, A.S.; Ghannoum, M.A.; King, T.R.; Azie, N.E.; Walsh, T.J. Ibrexafungerp, a novel triterpenoid antifungal in development for the treatment of mold infections. J. Fungi. 2022, 8, 1121.
  76. Rivero-Menendez, O.; Soto-Debran, J.; Cuenca-Estrella, M.; Alastruey-Izquierdo, A. In vitro activity of ibrexafungerp against a collection of clinical isolates of Aspergillus, including cryptic species and Cyp51A mutants, using EUCAST and CLSI methodologies. J. Fungi. Basel 2021, 7, 232.
  77. Rivero-Menendez, O.; Cuenca-Estrella, M.; Alastruey-Izquierdo, A. In vitro activity of olorofim (F901318) against clinical isolates of cryptic species of Aspergillus by EUCAST and CLSI methodologies. J. Antimicrob. Chemother. 2019, 74, 1586–1590.
  78. Seyedmousavi, S.; Chang, Y.C.; Law, D.; Birch, M.; Rex, J.H.; Kwon-Chung, K.J. Efficacy of olorofim (F901318) against Aspergillus fumigatus, A. nidulans, and A. tanneri in murine models of profound neutropenia and chronic granulomatous disease. Antimicrob. Agents Chemother. 2019, 63, e00129-19.
  79. Shaw, K.J.; Ibrahim, A.S. Fosmanogepix: A review of the first-in-class broad spectrum agent for the treatment of invasive fungal infections. J. Fungi. Basel 2020, 6, 239.
  80. Aliff, T.B.; Maslak, P.; Jurcic, J.G.; Heaney, M.L.; Cathcart, K.N.; Sepkowitz, K.A.; Weiss, M.A. Refractory Aspergillus pneumonia in patients with acute leukemia: Successful therapy with combination caspofungin and liposomal amphotericin. Cancer 2003, 97, 1025–1032.
  81. Kontoyiannis, D.P.; Hachem, R.; Lewis, R.E.; Rivero, G.A.; Torres, H.A.; Thornby, J.; Champlin, R.; Kantarjian, H.; Bodey, G.P.; Raad, I.I. Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies. Cancer 2003, 98, 292–299.
  82. Caillot, D.; Thiébaut, A.; Herbrecht, R.; de Botton, S.; Pigneux, A.; Bernard, F.; Larché, J.; Monchecourt, F.; Alfandari, S.; Mahi, L. Liposomal amphotericin B in combination with caspofungin for invasive aspergillosis in patients with hematologic malignancies: A randomized pilot study (Combistrat trial). Cancer 2007, 110, 2740–2746.
  83. Singh, N.; Limaye, A.P.; Forrest, G.; Safdar, N.; Muñoz, P.; Pursell, K.; Houston, S.; Rosso, F.; Montoya, J.G.; Patton, P.; et al. Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: A prospective, multicenter, observational study. Transplantation 2006, 81, 320–326.
  84. Marr, K.A.; Schlamm, H.T.; Herbrecht, R.; Rottinghaus, S.T.; Bow, E.J.; Cornely, O.A.; Heinz, W.J.; Jagannatha, S.; Koh, L.P.; Kontoyiannis, D.P.; et al. Combination antifungal therapy for invasive aspergillosis: A randomized trial. Ann. Int. Med. 2015, 162, 81–89.
  85. Lagrou, K.; Duarte, R.F.; Maertens, J. Standards of CARE: What is considered ‘best practice’ for the management of invasive fungal infections? A haematologist’s and a mycologist’s perspective. J. Antimicrob. Chemother. 2019, 74, ii3–ii8.
  86. Maertens, J.A.; Girmenia, C.; Brüggemann, R.J.; Duarte, R.F.; Kibbler, C.C.; Ljungman, P.; Racil, Z.; Ribaud, P.; Slavin, M.; Cornely, A.O.; et al. European guidelines for primary antifungal prophylaxis in adult haematology patients: Summary of the updated recommendations from the European Conference on Infections in Leukaemia. J. Antimicrob. Chemother. 2018, 73, 3221–3230.
  87. Kanj, S.S.; Omrani, A.S.; Al-Abdely, H.M.; Subhi, A.; El Fakih, R.; Abosoudah, I.; Kanj, H.; Dimopoulos, G. Survival outcome of empirical antifungal therapy and the value of early initiation: A review of the last decade. J. Fungi. 2022, 8, 1146.
  88. Pizzo, P.A.; Robichaud, K.; Gill, F.A.; Witebsky, F.G. Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Am. J. Med. 1982, 72, 101–111.
  89. Cordonnier, C.; Pautas, C.; Maury, S.; Vekhoff, A.; Farhat, H.; Suarez, F.; Dhédin, N.; Isnard, F.; Ades, L.; Kuhnowski, F.; et al. Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: A randomized, controlled trial. Clin. Infect. Dis. 2009, 48, 1042–1051.
  90. Maertens, J.; Lodewyck, T.; Donnelly, J.P.; Chantepie, S.; Robin, C.; Blijlevens, N.; Turlure, P.; Selleslag, D.; Baron, F.; Aoun, M.; et al. Empiric versus pre-emptive antifungal strategy in high-risk neutropenic patients on fluconazole prophylaxis: A randomized trial of the European organization for Research and Treatment of cancer (EORTC 65091). Clin. Infect. Dis. 2022.
  91. Fernandez-Cruz, A.; Lewis, E.R.; Kontoyiannis, D.P. How long do we need to treat an invasive mold disease in hematology patients? Factors influencing duration of therapy and future questions. Clin. Infect Dis. 2020, 71, 685–692.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
This entry is offline, you can click here to edit this entry!
ScholarVision Creations
Feedback